Potential use of histone deacetylase inhibitors in cancer therapy

Karolina Gołąbek; Joanna K. Strzelczyk; Andrzej Wiczkowski; Marek Michalski

doi:10.5114/wo.2015.51824

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2015
vol. 19

Send email

Copy url:

abstract:

Review paper

Potential use of histone deacetylase inhibitors in cancer therapy

Karolina Gołąbek

,

Joanna K. Strzelczyk

,

Andrzej Wiczkowski

,

Marek Michalski

Contemp Oncol (Pozn) 2015; 19 (6): 436–440

DOI: https://doi.org/10.5114/wo.2015.51824

Online publish date: 2015/05/28

View full text Get citation

PlumX metrics:

Epigenetics is a branch of science that focuses on mechanisms related to control and modification of expression of genetic material without any changes to its sequences. Such mechanisms include post-translational modifications of histones. It is widely known that carcinogenesis is related to hypoacetylation of genes that influence apoptosis, the cell cycle, cell signaling, the immunologic response, angiogenesis and occurrence of metastasis. Currently conducted research focuses on several strategies related to epigenetic therapy. One such strategy is based on the use of histone deacetylase inhibitors. This paper presents mechanisms through which these compounds work and a summary of their characteristics. It also includes a review of clinical tests related to histone deacetylase inhibitors, as well as their relationship with other chemotherapeutic methods. A better understanding of the involved mechanisms will provide a rational basis to improve the therapeutic outcome of available antitumor agents.

keywords:

Potential use of histone deacetylase inhibitors in cancer therapy

Karolina Gołąbek , Joanna K. Strzelczyk , Andrzej Wiczkowski , Marek Michalski

epigenetics, histone dea cetylase, histone deacetylase inhibitor, cancer therapy

Karolina Gołąbek

,

Joanna K. Strzelczyk

,

Andrzej Wiczkowski

,

Marek Michalski